A 2022 International Survey on the Status of Prostate Cancer Theranostics

The Journal of Nuclear Medicine

article

Thomas Beyer¹  Johannes Czernin²  Lutz Freudenberg³  Frederik Giesel⁴  Marcus Hacker⁵  Rodney J. Hicks⁶  Bernd J. Krause⁷ 

[1] QIMP Team, Centre Medical Physics and Biomedical Engineering, Medical University Vienna;Department of Molecular and Medical Pharmacology, UCLA;ZRN Rheinland;Department of Nuclear Medicine, Medical Faculty, Heinrich-Heine-University and University Hospital Duesseldorf;Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University Vienna;The Department of Medicine, St Vincent’s Hospital, the University of Melbourne;Rostock University Medical Centre, Department of Nuclear Medicine

关键词: prostate cancer;    PSMA;    Theranostics;    PET;    survey;   

DOI  :  10.2967/jnumed.122.264298

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

Growing interest in PSMA imaging using [68Ga]- or [18F]-labeled ligands and PSMA-based radioligand therapy (RLT) of prostate cancer (PCa) prompted us to survey the global community on their experiences and expectations. Methods: A web-based survey was composed to interrogate areas specific to PET imaging, the clinical value chain, and RLT applications. International responses were collected in early 2022. In total, over 300 valid responses were received and evaluated. Results: Most responses (83%) were given by nuclear medicine specialists with extensive experience in PET. At 22% of sites, PCa ranked “top” in cancer-type–specific PET indications, with an average and median of 15% and 10% of all cases, respectively. The most frequently used PSMA PET tracers were [68Ga]PSMA (32%) and [18F]PSMA-1007 (31%). Users reported a steady growth in PSMA PET and RLT over the past 5 y, averaging 50% and 82%, respectively, with a further 100% median growth projected over the next 5 y. Of note, more respondents indicated cognizance of personalized dosimetry than actually used it routinely. The most commonly identified barriers to future growth in PCa theranostics were radiopharmaceutical supply, reimbursement, staff availability, and buy-in of medical oncologists. Conclusion: Despite enthusiasm, this survey indicates variable adoption of PSMA imaging and RLT globally. Several challenges need to be addressed by the medical community, authorities, and patient advocacy groups in integrating PSMA-targeted theranostics into personalized medicine.

【 授权许可】

CC BY